Most health tech engineering teams building clinical decision support reach for a general-purpose vision-language model first. The reasoning is defensible: these models are capable, well-documented, and increasingly fine-tuned on medical image data. What gets underestimated is the architectural cost of keeping the generative pathway intact when the task does not require generation at all.
Companion piece to our broader work on medical AI architecture and regulatory readiness. See Cross-Modality Medical Imaging AI for Healthcare for guidance on domain adaptation trade-offs, generalisation risks, and architectural decisions for real-world deployment.
The Hidden Cost of Autoregressive Generation in Clinical Workflows
Standard vision-language models produce answers by generating tokens sequentially. For a conversational interface, that is appropriate. For a classification or triage task where the answer space is bounded, it introduces latency that scales with response length rather than with the complexity of the image.
This matters in clinical settings because inference time is not just a performance metric. It determines whether a tool integrates into a radiologist's reading session or sits outside it. A model that takes three seconds per image in isolation may take thirty under concurrent load, and that degradation is non-linear with autoregressive architectures.
The secondary cost is parsing. When a model produces free-form text, downstream logic must extract a structured decision from that output. That extraction step introduces its own failure modes, and those failures are difficult to characterise for regulatory purposes because they occur outside the model itself.
What a Single Forward-Pass Design Changes
The architectural alternative is to remove the generative pathway entirely and replace it with a decision head that scores candidate answers directly. MedJev, built on a Qwen3.5-4B backbone, demonstrates this pattern: the upper language layers and generative output are stripped, the full vision pathway is retained, and a decision head using query-key matching with a lightweight MLP residual maps directly from image and question to a scored decision (Zhang et al., HuggingFace 2026).
The result is that inference cost becomes fixed relative to the input, not the output. Latency no longer scales with the number of tokens the model would have generated. That is a structural property, not a tuning outcome, and it holds under load.
Zhang et al. report a 6.04x end-to-end speedup and a 7.93 percentage point accuracy improvement over the base model across four medical image benchmarks, with MedJev-4B outperforming all tested general and medical VLMs in the 4B to 9B parameter range on both accuracy and latency. These are not marginal gains achieved through optimisation tricks. They follow directly from removing a pathway that the task did not require.
Regulatory Validation Surface and What Architecture Has to Do With It
Clinical AI software that influences a diagnostic decision is subject to medical device regulation in most jurisdictions. The scope of that regulation depends in part on what the software does and how deterministically it does it. A model that produces free-form text and then has that text parsed into a decision has a larger and less well-defined validation surface than a model that produces a scored output directly.
Regulators and notified bodies want to understand the decision boundary. With a generative model, the boundary is partially defined by the parser sitting downstream. With a decision head architecture, the boundary sits inside the model itself and can be characterised through standard classification validation methods.
This does not make regulatory submission straightforward, but it makes the validation scope more tractable. Engineering teams that have been through a medical device software submission will recognise the difference between validating a classifier and validating a text generation pipeline with a downstream extraction layer. The former is harder to argue against.
Inference Cost at Scale and What It Means for Infrastructure Planning
At low volumes, the difference between autoregressive and direct decision inference is manageable. At the volumes that make a clinical AI product commercially viable, it is not. A radiology platform processing tens of thousands of studies per day is running a very different infrastructure problem depending on whether inference cost is fixed or variable per request.
Autoregressive models require GPU memory proportional to the KV cache, which grows with sequence length. Decision head models do not maintain a KV cache across generation steps because there are no generation steps. That changes the memory profile, the batching strategy, and the cost per inference unit.
For engineering leaders building cost models ahead of procurement or build decisions, this is the calculation that tends to be underweighted. The benchmark numbers are visible. The infrastructure cost at scale is not, until the architecture is already in production.
When to Evaluate This Pattern and When Not To
The direct decision architecture is the right choice when the task is bounded: classification, VQA with defined answer sets, triage scoring, structured reporting from a fixed schema. It is not the right choice when the clinical value depends on generating explanatory text that a clinician will read and act on independently.
The distinction matters because some teams conflate the model's ability to generate reasoning with the clinical utility of that reasoning. In many deployment contexts, the reasoning trace is never surfaced to the end user. It exists because the base model was trained to produce it, not because the workflow requires it. Removing it in those cases is not a capability reduction.
The evaluation question for engineering leaders is specific: does the downstream clinical workflow consume a structured decision, or does it consume free-form text? If the answer is the former, the generative pathway is overhead, and the architectural case for removing it is direct.
Where Vector Labs Fits
We build and certify production medical AI systems where architectural choices have direct regulatory consequences. In our cardiovascular certification work, we designed a custom architecture from scratch to meet Class 2A medical device software standards, achieving clinical-grade accuracy on wearable ECG data and delivering certification within the product launch timeline. If you are evaluating inference architecture for a clinical decision support product and want to pressure-test the build-versus-procure decision before it locks in, contact us at vector-labs.ai/contacts.
FAQs
Decision head architectures are well-suited to any task with a bounded answer space: binary classification, multi-class diagnosis, visual question answering with defined options, and structured triage scoring. They are not appropriate for tasks where the output is genuinely open-ended, such as generating a free-text radiology report from scratch. The practical question is whether your workflow actually requires open-ended generation or whether it requires a structured decision that has historically been wrapped in generated text for convenience.
Not if the architecture is designed correctly. The MedJev approach retains the full vision pathway and all visual tokens, removing only the upper language layers and the generative output head. The visual representation that the model builds is unchanged. What changes is how that representation is mapped to a decision, and the evidence from Zhang et al. suggests that a direct scoring mechanism can outperform the generative pathway on accuracy as well as speed.
A direct decision model produces a structured, deterministic output that can be validated using standard classification metrics: sensitivity, specificity, AUC, and subgroup performance. This is a well-understood validation framework for medical device software regulators. A generative model with a downstream parser requires you to validate both the model and the parser, and to characterise failure modes that arise at the interface between them. Reducing the validation surface to a single classification boundary is not a regulatory shortcut, but it does make the submission more tractable to scope and defend.
Autoregressive inference cost scales with the number of tokens generated per request, which is variable and often unpredictable under real-world prompt variation. At tens of thousands of requests per day, this variability compounds into significant GPU hour costs and makes capacity planning difficult. A decision head model has fixed inference cost per request regardless of what the equivalent generated response length would have been. That predictability is commercially significant when building a cost model for a product that needs to operate at clinical volumes.
The answer depends on whether an existing model's training distribution matches your imaging modality and task. A pre-built decision head model trained on general medical image benchmarks may not transfer to your specific imaging protocol without fine-tuning. The architectural pattern itself is not proprietary or complex to implement on top of an existing VLM backbone, but the training and validation work required to make it production-ready for a specific clinical task is non-trivial. Teams should evaluate whether the efficiency gains justify a build, or whether fine-tuning an existing decision model on domain-specific data is the more direct path.

